Given RIPK1’s roles in governing both immune and epithelial responses, using HSCT to cure these patients should be carefully considered, as it might ameliorate the immunodeficiency phenotype but not intestinal inflammation. The gene discussed is RIPK1; the disease is immune system disorder.